SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA...
5 KB (362 words) - 04:15, 25 March 2024
system function, inflammation and cancer. GSK-4112 GW501516 Nidufexor SR8278 SR9009 Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, et al. (March...
5 KB (379 words) - 14:24, 24 March 2024
GW0742 Irisin Peroxisome proliferator-activated receptor Sodelglitazar SR9009 Koh B (2013-03-22). "Anti-doping agency warns cheats on the health risks...
20 KB (1,953 words) - 04:39, 4 August 2024
conditions such as Duchenne muscular dystrophy and Alzheimer's disease. GSK4112 SR9009 SR9011 Kojetin D, Wang Y, Kamenecka TM, Burris TP (February 2011). "Identification...
3 KB (182 words) - 23:06, 1 April 2023
Alibhai FJ, Khatua TN, Rasouli M, Bridle BW, Burris TP, et al. (2019). "SR9009 administered for one day after myocardial ischemia-reperfusion prevents...
107 KB (12,592 words) - 21:51, 29 August 2024
(cardarine), an exercise mimetic that works as an agonist of the PPARβ/δ; and SR9009 (Stenabolic), an agonist of the Rev-Erb, which plays a role in circadian...
74 KB (6,761 words) - 06:35, 27 August 2024
GW501516, GW0742), AMP-activated protein kinase (AMPK) activators (AICAR, SR9009 (stenabolic)), meldonium (mildronate), trimetazidine HIF stabilizers, including...
9 KB (700 words) - 16:53, 7 May 2024
treatment of diabetic nephropathy and nonalcoholic steatohepatitis. GSK-4112 SR9009 SR9011 Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, et al...
2 KB (126 words) - 03:20, 6 April 2023
such as adipogenesis, regulation of bone density, and inflammation. SR8278 SR9009 SR9011 Grant D, Yin L, Collins JL, Parks DJ, Orband-Miller LA, Wisely GB...
5 KB (411 words) - 22:12, 3 February 2024